Alterity’s MRI Tool Proves It Can Track Brain Iron and Sharpen MSA Diagnosis
Peer-reviewed study validates QSM MRI as a precision biomarker for MSA
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) has announced the publication of a peer-reviewed study in NeuroImage validating quantitative susceptibility mapping (QSM) MRI as a biomarker for Multiple System Atrophy (MSA). The study, titled “Quantitative Imaging of Iron Dysregulation in Multiple System Atrophy,” was led by investigators at Vanderbilt University Medical Center in collaboration with Alterity. Its findings demonstrate that QSM can detect disease-specific iron accumulation, distinguish MSA from Parkinson’s disease, and track clinical severity — including in early-stage disease, where accurate diagnosis is particularly difficult. The publication carries direct implications for ATH434’s Phase 3 pathway, reinforcing the imaging strategy already deployed in Alterity’s Phase 2 programme.
CEO Commentary
“The bioMUSE study was designed to give us tools we could implement in our clinical program, and QSM is one of the valuable tools we identified… This peer-reviewed publication validates our approach and reinforces the role of QSM as a biomarker for iron-modulating therapies in MSA.”
— David Stamler, M.D., Chief Executive Officer, Alterity Therapeutics
When big ASX news breaks, our subscribers know first
What the bioMUSE study found — and why it matters
Study design at a glance
The study drew on longitudinal and cross-sectional data from Alterity’s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study, supplemented by additional cross-sectional data. The study population comprised four groups:
- 10 MSA patients followed prospectively over 12 months (longitudinal arm)
- 28 MSA patients included cross-sectionally
- 43 Parkinson’s disease (PD) patients included for comparison
- 23 age-matched healthy controls
Four key findings investors should note
-
Disease-specific iron accumulation. MSA patients showed significantly higher iron content in the lentiform nucleus (globus pallidus and putamen) versus both healthy controls and PD patients (all p<0.05), with the most pronounced effect observed in the globus pallidus.
-
Differentiation from Parkinson’s disease. Iron content in the globus pallidus distinguished MSA from PD with moderate-to-good accuracy (AUC = 0.76–0.79), with comparable performance in the early-stage subgroup — a setting in which clinical misdiagnosis is common.
-
Correlation with clinical severity. Higher iron content was significantly correlated with greater overall disease severity on the Unified Multiple System Atrophy Rating Scale (UMSARS), directly linking the imaging measure to patients’ functional and motor impairment.
-
Longitudinal progression. In preliminary 12-month analyses of the early-stage bioMUSE cohort, both the magnitude and spatial extent of abnormal iron accumulation increased progressively, paralleling clinical decline.
| Finding | Brain Region | Key Metric | Clinical Relevance | Phase 3 Implication |
|---|---|---|---|---|
| Disease-specific iron accumulation | Lentiform nucleus (globus pallidus and putamen) | Significantly higher iron vs controls and PD; all p<0.05 | Confirms MSA-specific pathological signature | Supports QSM as a target engagement biomarker for ATH434 |
| Differentiation from Parkinson’s disease | Globus pallidus | AUC = 0.76–0.79 | Enables earlier, more accurate MSA diagnosis | Supports patient selection and trial enrolment precision |
| Correlation with clinical severity | Lentiform nucleus | Significant correlation with UMSARS score | Links imaging measure to functional and motor impairment | Provides objective endpoint for measuring treatment response |
| Longitudinal progression | Multiple basal ganglia regions | Increasing magnitude and spatial extent over 12 months | Confirms iron accumulation tracks disease progression | Validates QSM as a longitudinal outcome measure in Phase 3 |
Chief Medical Advisor Commentary
“QSM provides an objective imaging signature that can help confirm the diagnosis of MSA and connect what we see in the brain to how patients are functioning… I look forward to the continued application of this technology in future clinical trials.”
— Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center, and Chief Medical Advisor, Alterity Therapeutics
Understanding QSM MRI — the imaging tool at the centre of Alterity’s strategy
Quantitative susceptibility mapping (QSM) MRI is an advanced neuroimaging technique that measures iron concentrations in specific brain regions with high precision, producing quantitative values rather than simply generating a visual scan. Conventional MRI cannot reliably quantify iron accumulation or reliably distinguish between diseases that share overlapping symptoms, which is a significant limitation in a condition like MSA where early clinical misdiagnosis is common.
In MSA, abnormal iron buildup is linked to α-synuclein aggregation — the pathological protein clumping that drives progressive neuronal loss. Put plainly, iron dysregulation is not a bystander in MSA; it is directly connected to the biological processes that cause the disease to worsen. Because QSM can measure iron burden objectively and track how it changes over time, it gives clinicians a window into the disease process at a neurological level that conventional imaging cannot provide.
This is where ATH434 becomes directly relevant. ATH434 is designed as an oral iron-modulating therapy, working by reducing this abnormal iron accumulation in the brain. Having an objective imaging tool that quantifies iron burden means clinicians can assess whether ATH434 is engaging its intended target — that is, whether the drug is actually reducing the iron load it is designed to address. Alterity used this QSM approach in its Phase 2 trial of ATH434, where it provided objective evidence of target engagement. The peer-reviewed validation published in NeuroImage strengthens the scientific foundation for carrying this approach into Phase 3.
The next major ASX story will hit our subscribers first
Phase 3 pathway taking shape — what comes next for Alterity
Alterity continues to advance ATH434 toward a Phase 3 programme for MSA. The company has received positive feedback from the U.S. Food and Drug Administration (FDA) following two recent Type C meetings, with alignment reached on clinical pharmacology, non-clinical development, and chemistry, manufacturing, and control (CMC) elements of the programme.
The next key milestone is an End-of-Phase 2 meeting with the FDA, which remains on track for mid-2026. This meeting is the gateway to initiating a pivotal Phase 3 trial in MSA. ATH434 currently holds the following regulatory designations:
- Fast Track Designation — U.S. FDA
- Orphan Drug Designation — U.S. FDA
- Orphan Drug Designation — European Commission
The clinical and commercial significance of reaching Phase 3 is considerable. MSA affects up to 50,000 individuals in the U.S. and there are currently no approved disease-modifying treatments for the condition. With a validated imaging biomarker, positive Phase 2 data, and a structured regulatory pathway in place, Alterity’s progress toward a pivotal trial represents a meaningful step in addressing one of neurology’s most significant unmet needs.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ investors who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.